TRDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Entrada Therapeutics Inc (TRDA) is not a strong buy for a beginner, long-term investor at this moment. While analysts have a positive outlook with price targets nearly double the current price, the lack of positive trading signals, insider selling, and weak financial performance suggest waiting for a more favorable entry point.
The MACD histogram is negative (-0.0853) and contracting, indicating bearish momentum. RSI is neutral at 46.762, and moving averages are converging, showing no clear trend. The stock is trading slightly above its pivot level (10.95), with resistance at 11.825 and support at 10.076.
The stock is considered undervalued compared to peers.
Insiders are selling, with a 374.09% increase in selling activity over the last month. Financial performance is weak, with a significant revenue drop (-91.75% YoY) and negative net income (-$44.13M). No recent news or congress trading data to support a bullish sentiment.
In Q3 2025, revenue dropped significantly (-91.75% YoY) to $1.61M. Net income improved to -$44.13M (+214.52% YoY), but the company remains unprofitable. EPS improved to -1.06 (+202.86% YoY), and gross margin remained at 100%.
Analysts from Guggenheim and Oppenheimer have initiated coverage with 'Buy' or 'Outperform' ratings and price targets of $20-$21, citing the company's potential in addressing a $1.4Bn market and its catalyst-rich pipeline.
